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Abstract
Aims
β-amyloid (Aβ) plaques are a key feature of Alzheimer’s disease pathology but correlate
poorly with dementia. They are associated with astrocytes which may modulate the effect of
Aβ-deposition on the neuropil. This study characterised the astrocyte response to Aβ pla-
que subtypes, and investigated their association with cognitive impairment.
Methods
Aβ plaque subtypes were identified in the cingulate gyrus using dual labelling immunohis-
tochemistry to Aβ and GFAP+ astrocytes, and quantitated in two cortical areas: the area of
densest plaque burden and the deep cortex near the white matter border (layer VI). Three
subtypes were defined for both diffuse and compact plaques (also known as classical or
core-plaques): Aβ plaque with (1) no associated astrocytes, (2) focal astrogliosis or (3)
circumferential astrogliosis.
Results
In the area of densest burden, diffuse plaques with no astrogliosis (β = -0.05, p = 0.001) and
with focal astrogliosis (β = -0.27, p = 0.009) significantly associated with lower MMSE
scores when controlling for sex and age at death. In the deep cortex (layer VI), both diffuse
and compact plaques without astrogliosis associated with lower MMSE scores (β = -0.15,
p = 0.017 and β = -0.81, p = 0.03, respectively). Diffuse plaques with no astrogliosis in layer
VI related to dementia status (OR = 1.05, p = 0.025). In the area of densest burden, diffuse
plaques with no astrogliosis or with focal astrogliosis associated with increasing Braak
stage (β = 0.01, p<0.001 and β = 0.07, p<0.001, respectively), and ApoEε4 genotype
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(OR = 1.02, p = 0.001 and OR = 1.10, p = 0.016, respectively). In layer VI all plaque sub-
types associated with Braak stage, and compact amyloid plaques with little and no associat-
ed astrogliosis associated with ApoEε4 genotype (OR = 1.50, p = 0.014 and OR = 0.10, p =
0.003, respectively).
Conclusions
Reactive astrocytes in close proximity to either diffuse or compact plaques may have a neu-
roprotective role in the ageing brain, and possession of at least one copy of the ApoEε4 al-
lele impacts the astroglial response to Aβ plaques.
Introduction
Neuropathologically Alzheimer’s disease (AD) is a progressive neurodegenerative disorder
characterised by β-amyloid (Aβ) plaques (diffuse and compact dense-core) and intracellular
tangles of hyperphosphorylated tau [1]. Aβ plaque formation is thought to progress from dif-
fuse through to compact [2,3]. The relative frequency of the plaque subtypes changes during
the progression of AD, with diffuse Aβ plaques being prevalent in the preclinical stages and
compact plaques increasing in frequency as the disease progresses [4,5]. The Medical Research
Council’s population-based Cognitive Function and Ageing Study (CFAS) has shown that
Alzheimer-type pathology is the most common pathology associated with dementia in the age-
ing population [6], but that there is considerable overlap in the burden of plaques and tangles
between individuals with or without dementia, especially in the oldest old [7,8], suggesting
other factors contribute to the progression of cognitive decline.
Astrocytes, the most abundant glial cell, play a critical role in neuronal support and in main-
taining homeostasis within the central nervous system (CNS) [9]. Activated glia surround and
infiltrate Aβ plaques in AD [10–12], however their exact role in the pathogenesis of age-related
neuropathology remains unknown. While astrocytes have been shown to play a significant role
in the degradation and clearance of Aβ suggesting a neuroprotective role [13], other studies
have shown astrocyte activation results in the production of critical inflammatory mediators,
suggesting they play a detrimental role in the progression of age-related neurodegenerative pa-
thology [14]. Reactive astrocytes up-regulate glial fibrillary acidic protein (GFAP) expression
in response to CNS insults [15,16]. Astrogliosis and astrocyte dystrophy are prominent features
of several dementia pathologies, including AD and frontotemporal dementia, where the degree
of astrocyte degeneration correlates with the severity of dementia [17]. Astrogliosis occurs at
early stages of AD pathogenesis and treatment of cultured astrocytes with aggregated Aβ or
with amyloid isolated from human AD brains has been shown to trigger astrogliosis [18–20].
Recent studies have further characterised the astroglial response in AD, demonstrating an in-
crease in plaque-associated GFAPα and GFAPδ isoforms, and although the number of astro-
cytes expressing the GFAP(+1) isoform correlates with AD progression, they are not associated
with plaques [12]. Possession of the ApoEε4 allele, a major genetic risk factor for AD [21], is as-
sociated with an increased cortical Aβ plaque burden [22–24] and astrocyte dysfunction [25].
ApoE4, primarily expressed by astrocytes in the brain, plays a role in the metabolism of amy-
loid [26,27], and has been shown to promote Aβ deposition [28].
The CFAS neuropathology cohort is population-based thus allowing unbiased assessment
of pathologies in brain ageing and their relationships to cognitive impairment [6–8]. We have
previously characterised the astrocyte phenotype in the CFAS cohort and demonstrated
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increased GFAP immunoreactivity associated with increasing Braak and Braak neurofibrillary
tangle stage with some, but not all, Aβ plaques associated with GFAP+ astrocytes [29]. We
hypothesised that the astrocyte response to Aβ deposits in the cingulate gyrus may modulate
the effect of the amyloid plaque on surrounding brain tissue, and therefore on cognition. This
region was selected as it contributes to spatial learning and memory [30], is associated with a
high prevalence of Aβ pathology. It is involved in the intermediate stages of Aβ progression
(Aβ phase 3/5), [31], is involved in the limbic stage of neurofibrillary tangle progression (Braak
and Braak stage III-IV) and has projections to the entorhinal cortex, the area with the earliest
NFT formation [32], and presents with metabolic and vascular changes before the development
of AD [33,34]. Therefore the aim of this study was to examine the variation in the astrocyte re-
sponse associated with both diffuse and compact Aβ plaques in the cingulate gyrus, and investi-
gate their association with Braak and Braak stage, cognitive impairment, dementia status and
ApoE genotype.
Materials and Methods
Human CNS cases
Human CNS material was obtained from the Medical Research Council Cognitive Function
and Ageing Study (MRC CFAS) autopsy cohort, which has been described in detail previously
[35,36]. Individuals selected for the assessment interviews were approached by a trained liaison
officer for brain donation in each centre, who discussed the donation programme with the re-
spondent and his or her family or carers, as appropriate. When an individual died and the re-
search team was notified, the next of kin was approached to give consent for brain donation
and retention. Limited or full necroscopy then proceeded if all permissions were obtained.
Multi-centre research ethics committee (REC) approval for the current study was obtained
from Cambridgeshire 1 Research Ethics Committee (REC reference number 10/H0304/61).
The study used all of the cases derived from one of the CFAS centres (Cambridge), thereby
maintaining the unbiased, population-based nature of the study. Cortical blocks were sampled
within 4–6 weeks following a standard protocol [37], from 109 formalin-fixed cases. Neuro-
pathological lesions were assessed as part of the core CFAS neuropathology study using a mod-
ified protocol from the Consortium to Establish a Registry of Alzheimer’s Disease (CERAD)
[38] (wwws.cfas.ac.uk). Braak and Braak staging was assessed by analysis of AT8 immunostain-
ing of neurofibrillary tangles in the hippocampus and isocortical regions [32,39]. The cases
were categorised into groups representing entorhinal stages (Braak stages 0–2; 27 cases), limbic
stages (Braak stages 3–4; 50 cases) and isocortical stages (Braak stages 5–6; 22 cases). ApoE ge-
notype was previously determined in the cohort [40,41].
Individuals in the study were regularly interviewed and underwent Geriatric Mental State-
Automated Geriatric Examination for Computer-Assisted Taxonomy (GMS-AGECAT), Cam-
bridge Mental Disorders of the Elderly Examination (CAMDEX), and mini mental state exami-
nation (MMSE) [7,8]. Dementia status at death was determined on the basis of all information
available for each participant, as previously described [8,35]. Within this cohort, 68 partici-
pants had dementia, 39 had no dementia and 2 participants had an unknown dementia status
at death due to the lack of information in the years preceding death (Table 1). Twenty-one
participants with dementia and 9 participants with no dementia possessed at least one ApoEε4
allele.
Immunohistochemistry
Immunohistochemistry of formalin-fixed, paraffin-embedded sections (5μm) from the cingu-
late cortex was performed using a standard avidin-biotin complex (ABC) method. Sections
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were deparaffinised, rehydrated to water and endogenous peroxidase activity quenched by
placing the sections in 0.3% H2O2/methanol for 20min at room temperature (RT). Sections
were subjected to antigen retrieval (0.01M tri-sodium citrate pH6.5, microwave 10min) fol-
lowed by formic acid pre-treatment for 60min at RT. Following incubation with 1.5% normal
serum for 30min at RT, the sections were incubated with anti-Aβ (Clone 6F/3D; DakoCytoma-
tion, UK) [42] at the optimal antibody dilution of 1:200 for 60min at RT. To visualise antibody
binding, the horse-radish peroxidase avidin biotin complex was used (Vectastain Elite kit,
Vector Laboratories, UK) with 3,3’-diaminodenzidine (DAB) as the chromagen (Vector
Laboratories, UK; brown). Following incubation with the avidin-biotin blocking kit (Vector
Laboratories, UK), sections were incubated overnight at 4°C with anti-GFAP (1:500; DakoCy-
tomation, UK) [43], followed by the alkaline-phosphatase-conjugated avidin-biotin complex
(Vectastain Elite kit, Vector Laboratories, UK), developed with alkaline phosphatase substrate
1 (Vector Laboratories, UK; red) and lightly counterstained with Mayer’s haematoxylin. Nega-
tive controls, either omission of the primary antibody or isotype controls, were included in
every run.
Quantitative neuropathological analysis
Assessment of Aβ and GFAP immunoreactivity was conducted using a Nikon Eclipse Ni-U mi-
croscope and Nikon DS-Ri1 camera with NIS-Elements BR 4.20.01 64-bit microscope imaging
software (Nikon, UK). Aβ plaques were subtyped based on the type of plaque (diffuse or com-
pact) and the surrounding astrocyte reaction. Compact plaques are spherical in shape and are
characterised by a dense central core of Aβ surrounded by a less compact peripheral halo, in
contrast to the diffuse plaques which are usually not spherical and stain weakly for Aβ [44].
Compact plaques may be associated with tau-positive dystrophic neurites, which are then re-
ferred to as neuritic plaques. However, triple labelling with Aβ, GFAP and tau was not per-
formed, therefore neuritic plaques containing dystrophic neurites were not assessed as part of
this study. The frequency and grade (none, mild, moderate or severe) of both diffuse and com-
pact Aβ plaques were assessed in single Aβ immunostained cingulate gyrus sections, based on
the CERAD protocol [38].
Three subtypes were defined for both diffuse and compact plaques: (1) Aβ plaque with no
associated astrocytes, (2) focal astrogliosis and (3) circumferential astrogliosis. Focal astroglio-
sis was defined as reactive astrocytes directly in contact with a plaque solely on one of its bor-
ders. Circumferential astrogliosis was defined as reactive astrocytes directly in contact with and
completely surrounding a plaque. Areas of astrogliosis remote from plaques were also identi-
fied and defined as small (less than two distinct GFAP+ astrocytes) and large (greater than or
equal to three distinct GFAP+ astrocytes). The number of each plaque subtype was quantitated
in the area with the densest of amyloid burden under the 10x objective (field area 1275 x
925 μm2). Micro-plaques (<10μm in diameter) and plaques in layer I of the cortex were
Table 1. Demographic and cognitive proﬁle of cases, according to dementia status.
No dementia (n = 39) Dementia (n = 68)
Sex (male:female) 16:23 22:46
Age at death (y)* 84 (76–88) 89 (84–93)
Years since last cognitive assessmenta 1.5 (1.0–1.9) 1.7 (0.8–3.0)
MMSE at last assessment* 24 (20–27) 14 (6–20)
amedian (interquartile range)
doi:10.1371/journal.pone.0118463.t001
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ignored and did not contribute to the count. Using an identical method, the number of each
plaque subtype was also assessed in four fields of the deep cortex (layer VI) (5100 x 925 μm2),
in areas remote from the area of densest amyloid burden.
Inter-rater reliability of Aβ plaque subtype quantitation
The number and subtype of Aβ plaques and non-plaque associated regions of astrogliosis were
quantitated in the area of densest burden in a subset of 10 randomly selected cases by two inde-
pendent observers (RM and JES), and the extent of agreement assessed by calculating Gwet’s
AC2 coefficients [45]. The coefficient calculations were performed using Agreestat 2011.2 pro-
gramme (Advanced Analytics, Gaithersburg, MD, USA), and the extent of agreement was as-
sessed using the benchmark proposed by Landis and Koch [46], a coefficient>0.6 indicating
substantial agreement and a value>0.8 near-perfect agreement.
There was near-perfect agreement in the scoring of diffuse plaques with no associated astro-
cytes (AC2 = 0.86, 95%CI(AC2) 0.62; 1.00), diffuse plaques with focal astrogliosis (AC2 = 0.88,
95%CI(AC2) 0.75; 1.00), compact plaques with no associated astrocytes (AC2 = 0.83, 95%CI
(AC2) 0.61; 1.00), compact plaques with circumferential astrogliosis (AC2 = 0.86, 95%CI(AC2)
0.65; 1.00) and large areas of non-plaque associated astrogliosis (AC2 = 0.93, 95%CI(AC2)
0.76; 1.00). There was a substantial agreement in the scoring of diffuse plaques with circumfer-
ential astrogliosis (AC2 = 0.76, 95%CI(AC2) 0.36; 1.00), compact plaques with focal astrocytes
(AC2 = 0.79, 95%CI(AC2) 0.42; 1.00) as well as small areas of non-plaque associated astroglio-
sis (AC2 = 0.75, 95%CI(AC2) 0.29; 1.00), confirming the reliability of the scoring method.
Subsequent analyses of the number and subtype of Aβ plaques and non-plaque associated re-
gions of astrogliosis in the cohort were performed on scores by RM.
Statistical Analysis
Statistical analyses were performed and graphs obtained using IBM SPSS Statistics 21 (Armonk,
NY) and Stata Statistical Software 12 (College Station, TX). The association between Braak and
Braak neurofibrillary tangle stage and the frequency of either diffuse or compact Aβ plaques was
assessed using Kendall’s tau correlation coefficient. The relationships between plaque subtype
with Braak and Braak stage andMMSE score were tested via multiple linear regression analysis
where MMSE score and Braak and Braak stage were the dependent variables, whereas the rela-
tionships between plaque subtype with dementia status and ApoE genotype were verified using
logistic regression, where dementia status and E4 ApoE genotype were the dependent variables.
All the regression analyses were controlled by sex and age at death.
Results
Aβ plaque subtypes in the ageing brain
Diffuse and compact Aβ plaques were diverse in size, number and distribution throughout
the cohort. The frequency of each grade (none, mild, moderate or severe) of diffuse and com-
pact Aβ amyloid plaque in the cingulate gyrus is shown in Table 2. Both diffuse (τ = 0.333,
p<0.001) and compact (τ = 0.259, p = 0.001) Aβ plaques associated with Braak and Braak neu-
rofibrillary tangle stage.
Six distinct Aβ plaque subtypes were identified in the ageing cohort: (1) diffuse plaques with
no associated astrocytes (Fig. 1A); (2) compact plaques with no associated astrocytes (Fig. 1B);
(3) diffuse plaques with focal astrogliosis (Fig. 1C); (4) compact plaques with focal astrogliosis
(Fig. 1D); (5) diffuse plaques with circumferential astrogliosis (Fig. 1E); (6) compact plaques
with circumferential astrogliosis (Fig. 1F).
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Both small (Fig. 2A) and large areas of astrogliosis (Fig. 2B) were also detected in regions re-
mote from plaques. Initial investigation of the cohort noted that clusters of plaques with associ-
ated reactive astrocytes were frequently observed in the deep cortex near the white matter
border (layer VI) (Fig. 2C), distinct from the areas of densest amyloid burden in layers I-V
(Fig. 2D), therefore Aβ plaque subtype was assessed in both regions.
Association of Aβ plaque subtype with Braak stage
In the area of densest burden diffuse plaques with no astrogliosis (β = 0.01, p<0.001) or with
focal astrogliosis (β = 0.07, p<0.001) significantly associated with increasing Braak and Braak
neurofibrillary tangle stage (Table 3). In layer VI, diffuse plaques with no (β = 0.04, p<0.001),
focal (β = 0.08, p<0.001) or circumferential astrogliosis (β = 0.2, p = 0.003), as well as compact
plaques with no (β = 0.21, p = 0.001), focal (β = 0.38, p<0.001) or circumferential astrogliosis
(β = 0.45, p = 0.001) significantly associated with Braak stage (Table 4). Large areas (β = -0.32,
p = 0.043), but not small areas (β = 0.02, p = 0.413), of non-plaque associated astrogliosis sig-
nificantly associated with Braak stage.
Aβ plaques with little or no associated astrogliosis correlate with
cognitive impairment
In the area of densest burden, diffuse Aβ plaques with no astrogliosis (β = -0.05, p = 0.001) or
with focal astrogliosis (β = -0.27, p = 0.009) significantly associated with lower MMSE scores
(Table 3). In layer VI, both diffuse plaques and compact plaques without astrogliosis signifi-
cantly associated with lower MMSE scores (β = -0.15, p = 0.017 and β = -0.81, p = 0.03, respec-
tively) (Table 4). Only diffuse plaques with no astrogliosis in the deep cortex significantly
related to dementia status (p = 0.025) (Table 3). Neither small nor large areas of non-plaque as-
sociated astrogliosis associated with either MMSE scores (β = -0.24, p = 0.114 and β = -0.25,
p = 0.791, respectively) or dementia status (p = 0.248 and p = 0.558).
Association of Aβ plaque subtype with ApoE genotype
Possession of at least one ApoEε4 allele was significantly associated with a greater number of
diffuse plaques with no (OR = 1.02, p = 0.001) or focal astrogliosis (OR = 1.10, p = 0.016) in
the region of densest burden (Table 3), and with compact plaques with no (OR = 1.77, p =
0.003) or focal astrogliosis (OR = 1.50, p = 0.014) in layer VI (Table 4). Neither small (OR =
0.92, p = 0.313) nor large (OR = 0.89, p = 0.693) areas of non-plaque associated astrogliosis as-
sociated with ApoE genotype. A summary of the major Aβ plaque subtype associations with
Braak stage, general cognition (MMSE) and possession of the ApoEε4 allele is shown in
Table 5.
Table 2. Frequency of diffuse and compact Aβ plaques in the cingulate gyrus, based on the CERAD protocol.
Grade Frequency (no of cases) Percentage of cases
Diffuse Aβ plaques None 13 11.9
Mild 26 23.9
Moderate 29 26.6
Severe 41 37.6
Compact Aβ plaques None 29 26.6
Mild 43 39.4
Moderate 37 33.9
doi:10.1371/journal.pone.0118463.t002
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Fig 1. Aβ plaque subtypes in the ageing brain. Six distinct Aβ plaque subtypes were identified in the ageing cohort: (a) diffuse plaques with no associated
astrocytes; (b) compact plaques (also known as classical or core plaques) with no associated astrocytes; (c) diffuse plaques with focal astrogliosis; (d)
compact plaques with focal astrogliosis; (e) diffuse plaques with circumferential astrogliosis; (f) compact plaques with circumferential astrogliosis, as
indicated by the arrow. Scale bar represents 50μm
doi:10.1371/journal.pone.0118463.g001
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Discussion
Several studies have demonstrated an association between Aβ plaques and astrogliosis; however
whether these reactive astrocytes are actively contributing to ongoing neurodegenerative pro-
cesses or play a neuroprotective role is highly debated [11,13,14,47]. The results of the current
study demonstrate that astrogliosis associated with both diffuse and compact plaques in the
area of densest burden and in the deep cortex (layer VI) negatively relates to cognitive im-
pairment, and that possession of at least one copy of the ApoEε4 allele impacts the astroglial re-
sponse to Aβ plaques.
The amyloid cascade hypothesis is currently the major theory of AD pathogenesis [48],
however therapies based on removal of A have, to date, been disappointing [49]. Population-
based studies have shown a weak association of amyloid pathologies with dementia [36,50],
suggesting other factors contribute to cognitive impairment in the ageing brain. An additional
possibility may be population variation in the response to Aβ deposits, with some individuals
better able to prevent toxic effects on the surrounding neuropil. Inter-individual variation in
Fig 2. Astrogliosis remote from Aβ plaques, Aβ plaques in layer VI and regions of densest plaque burden. Both (a) small and (b) large areas of
astrogliosis were detected in regions remote from Aβ plaques, as indicated by the arrow. (c) Clusters of plaques with associated reactive astrocytes were
frequently observed in the deep cortex (layer VI) near the white matter border (WM), distinct from (d) the areas of densest amyloid burden. Scale bar
represents 50μm (a) and 100μm (b-d).
doi:10.1371/journal.pone.0118463.g002
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the astrocyte response to Aβ deposition may be a part of this, and furthermore, ApoE genotype
may be one regulator of the astrocyte response.
Amyloid plaque development starts in the superficial layers of the cortex and extends to the
deep cortex as pathology progresses [51]. Increased levels of diffuse plaques without astroglio-
sis, but not plaque number, in both areas of densest burden and cortical layer VI demonstrated
a significant association with lower MMSE scores, suggesting astrocytes play a neuroprotective
role when associated with amyloid deposits. Diffuse, but not compact, plaques with no astro-
gliosis in layer VI strongly associated with dementia status.
In contrast to compact plaques which contain the fibrillar form of Aβ, diffuse plaques con-
tain pre-fibrillary Aβ and may represent a precursor in plaque development [52]. The different
composition of plaques may result in differences in toxicity, as intermediate forms of amyloid
are considered as one of the most neurotoxic species of Aβ [1]. Intraneuronal accumulation of
Table 3. Association of Aβ plaque subtype in the area of densest Aβ burden with Braak stage, general cognition (MMSE), dementia status and
possession of ApoEε4 allele.
Braaka (n = 101) MMSEa (n = 107) Dementiab (n = 107) ApoEε4b (n = 83)
Aβ plaque subtype β 95%CI(β) p β 95%CI(β) p OR 95%CI(OR) p OR 95%CI(OR) p
Diffuse plaque
No astrogliosis 0.04 (0.02; 0.06) <0.001 -0.05 (-0.08; -0.02) 0.001 1.01 (1.00; 1.01) 0.187 1.02 (1.01; 1.03) 0.001
Focal astrogliosis 0.08 (0.03; 0.12) <0.001 -0.27 (-0.47; -0.07) 0.009 1.06 (0.99; 1.14) 0.081 1.10 (1.02; 1.19) 0.016
Circumferential astrogliosis 0.20 (0.07; 0.32) 0.003 -0.36 (-1.95; 1.24) 0.659 1.13 (0.74; 1.74) 0.567 1.33 (0.87; 2.03) 0.187
Compact plaque
No astrogliosis 0.21 (0.09; 0.33) 0.001 -0.73 (-1.59; 0.14) 0.100 1.09 (0.88; 1.35) 0.447 1.07 (0.85; 1.36) 0.559
Focal astrogliosis 0.38 (0.21; 0.55) <0.001 -0.38 (-2.11; 1.34) 0.659 1.63 (0.96; 2.76) 0.071 1.26 (0.81; 1.94) 0.302
Circumferential astrogliosis 0.45 (0.18; 0.72) 0.001 -1.46 (-4.04; 1.12) 0.265 1.21 (0.53; 2.77) 0.648 1.11 (0.60; 2.04) 0.744
amultiple linear regression analyses used with MMSE score and Braak and Braak stage as dependent variables (test statistic: regression coefﬁcient: β,
beta).
blogistic regression analyses used dementia status and ApoE genotype as dependent variables (test statistic: odds ratio (OR) CI: conﬁdence interval.
doi:10.1371/journal.pone.0118463.t003
Table 4. Association of Aβ plaque subtype in the deep cortex (layer VI) with Braak stage, general cognition (MMSE), dementia status and
possession of ApoEε4 allele.
Braaka (n = 101) MMSEa (n = 107) Dementiab (n = 107) ApoEε4b (n = 83)
Aβ plaque subtype β 95%CI(β) p β 95%CI(β) p OR 95%CI(OR) p OR 95%CI(OR) p
Diffuse plaque
No astrogliosis 0.01 (0.01; 0.02) <0.001 -0.15 (-0.28; -0.03) 0.017 1.05 (1.01; 1.10) 0.025 1.04 (1.00; 1.07) 0.064
Focal astrogliosis 0.07 (0.04; 0.10) <0.001 -0.15 (-0.43; 0.13) 0.288 1.09 (1.00; 1.19) 0.061 1.08 (1.00; 1.17) 0.054
Circumferential astrogliosis 0.21 (-0.04; 0.45) 0.093 0.04 (-0.82; 0.89) 0.934 1.06 (0.84; 1.33) 0.624 1.17 (0.95; 1.45) 0.141
Compact plaque
No astrogliosis 0.12 (-0.01; 0.25) 0.064 -0.81 (-1.54; -0.08) 0.030 1.21 (0.93; 1.58) 0.154 1.77 (1.21; 2.59) 0.003
Focal astrogliosis 0.14 (-0.14; 0.41) 0.326 -0.64 (-1.76; 0.48) 0.261 1.29 (0.93; 1.79) 0.120 1.50 (1.09; 2.07) 0.014
Circumferential astrogliosis 0.03 (-0.37; 0.42) 0.892 -1.24 (-3.07; 0.58) 0.181 1.16 (0.71; 1.89) 0.552 1.13 (0.70; 1.82) 0.619
amultiple linear regression analyses used with MMSE score and Braak and Braak stage as dependent variables (test statistic: regression coefﬁcient: β,
beta).
blogistic regression analyses used dementia status and ApoE genotype as dependent variables (test statistic: odds ratio (OR) CI: conﬁdence interval.
doi:10.1371/journal.pone.0118463.t004
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Aβ, rather than extracellular Aβ deposition may contribute to neuronal dysfunction and drive
AD pathology [53–55]. Future studies aimed at specifically assessing the association between
astrogliosis and intraneuronal Aβ are required. We cannot demonstrate how reactive astrocytes
might promote neuronal survival but they have been shown to protect neurones by regulating
extracellular ion concentrations and neurotransmitter recycling [56], secreting neurotrophic
factors [57], and to modulate Aβ-mediated neurotoxicity in vitro, safeguarding against neuro-
nal dystrophy and synaptic loss [58]. Furthermore, astrocytes can degrade, internalise and
clear Aβ [13,28,59], and have been shown to regulate microglial phagocytosis of compact pla-
que cores [20]. Our data suggests that astrocytes may form a protective barrier around amyloid
plaques, demarcating the area for Aβ degradation, phagocytosis and a local inflammatory reac-
tion. This would predict that plaques that are not insulated by astrocytes have a greater toxic ef-
fect on surrounding brain tissue. However, further investigations are required to confirm and
characterise the neuroprotective role of astrocytes in response to Aβ plaque formation.
In the area of densest amyloid burden diffuse plaques with no, or focally, associated reactive
astrocytes, but not with circumferential astrogliosis, demonstrated a significant association
with Braak stage while all compact plaque subtypes showed a significant association with Braak
stage, confirming the increasing burden of amyloid plaques in the cingulate gyrus mirrors the
progression of tau pathology in the ageing brain [60]. The lack of association between diffuse
plaques with circumferential astrogliosis and Braak stage suggests that the astrocyte reaction to
plaque formation occurs at the earliest stages of tangle pathology, and does not directly parallel
amyloid deposition [11]. Large regions of non-plaque associated astrogliosis showed no rela-
tion to dementia status or cognitive impairment, but did significantly associate with increasing
Braak stage, supporting studies which suggest these astrogliotic lesions parallel neurofibrillary
tangle progression and react to the burden of neurofibrillary tangles in the ageing brain
[11,61]. AD is characterised by early damage to synapses [62,63] and dendritic atrophy [64].
Further work is required to investigate if the regions of non-plaque associated astrogliosis
Table 5. Summary of the major Aβ plaque subtype associations with Braak stage, general cognition (MMSE) and possession of the ApoEε4
allele.
Diffuse Aβ plaque
Associated astrocytes none focal
densest burden Layer VI densest burden Layer VI
increasing Braak stage <0.001 <0.001 <0.001 <0.001
decreasing MMSE 0.001 0.017 0.009 0.288
possession of ApoEε4 0.001 0.064 0.016 0.054
Compact Aβ plaque
Associated astrocytes none focal
densest burden Layer VI densest burden Layer VI
increasing Braak stage 0.001 0.064 <0.001 0.326
decreasing MMSE 0.100 0.030 0.659 0.261
possession of ApoEε4 0.559 0.003 0.302 0.014
Diffuse Aβ plaques with no or focal astrogliosis in the area of densest burden associated with increasing Braak stage, decreasing MMSE and possession
of at least one ApoEε4 allele. Diffuse Aβ plaques with no astrogliosis in layer VI associated with increasing Braak stage and decreasing MMSE score.
Diffuse plaques with focal astrogliosis associated with increasing Braak stage. Compact Aβ plaques with no or focal astrogliosis in the area of densest
burden associated with Braak stage. Compact Aβ plaques with no astrogliosis in layer VI associated with a decreasing MMSE score. Compact Aβ plaques
with no or focal astrogliosis in layer VI associated with possession of at least one ApoEε4 allele.
doi:10.1371/journal.pone.0118463.t005
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detected in this study reflect astrocyte reaction to dendritic degeneration and synaptic loss
[60,65].
Possession of a single copy of the ApoEε4 allele is associated with a significant increased risk
of developing AD [21,26], increased numbers of Aβ plaques [24], increased accumulation of
intraneuronal Aβ [66] and elevated levels of astrogliosis [67]. In contrast to previous reports
that ApoEε4 genotype does not impact glial responses to plaques in AD studies [47], the cur-
rent findings demonstrate that in the area of densest Aβ burden diffuse amyloid plaques with
little or no associated astrogliosis are significantly higher in ApoEε4 carriers in the ageing pop-
ulation. Although studies have demonstrated a significant correlation between compact pla-
ques and ApoE genotype in AD [68,69], only compact plaques with no or focal astrogliosis in
layer VI correlated with ApoE genotype. We have previously shown that astrocyte dysfunction
in association with the progression of Alzheimer-type pathology is an early event for ApoEε4
carriers in this ageing cohort [25], and propose that this ApoEε4-associated astrocyte dysfunc-
tion may explain the lack of association with plaques with circumferential astrogliosis, and the
significant association between increased levels of plaques with no or little astrogliosis and
ApoE genotype.
In addition to an astrocyte response to Aβ plaques, microglial activation is also a prominent
feature of AD pathology [70,71], and is associated with the degradation and clearance of Aβ
[72,73]. While the activation and recruitment of microglia may occur in tandem with astroglio-
sis, studies have shown that reactive astrocytes and activated microglia respond differently to
Aβ plaque formation and development [47], with activated microglia associated with prolifera-
tion and the secretion of pro-inflammatory cytokines [74]. Furthermore, CNS injury is associ-
ated with crosstalk between astrocytes and microglia involving a cytokine network, which
regulates glial activation and impacts neuronal survival [75]. Future studies assessing microglial
activation in addition to astrogliosis will enable a detailed characterisation of the glial response
to Aβ plaque formation in the ageing brain.
The current study examined the astrocyte response to amyloid plaques solely in the cingu-
late gyrus, a region associated with metabolic and vascular changes in the very early stages of
AD [33,34]. Expanding the investigation to include additional brain regions is essential to pro-
vide further validation to the findings reported here. In this study, the detection of plaques
without associated astrocytes in a single section may have failed to detect a focal astrocyte re-
sponse associated with larger Aβ plaques which span several sections. Quantitation of the num-
ber and subtype of plaques in serial sections, as opposed to a single field, would enable a three-
dimensional astrocyte response to Aβ plaques to be determined. Further investigation into
areas of reactive astrocytes remote from Aβ plaques should be performed to enable clearer defi-
nition of these lesions with respect to other local pathological features including synaptic loss,
dendritic atrophy, tau pathology and microglial activation, as discussed above.
The current population-based study of the astrocyte response to amyloid plaques demon-
strates clear relationships between Aβ plaque subtypes and cognitive impairment. Our findings
may indicate a neuroprotective role of plaque-associated astrocytes, and suggest that astroglio-
sis may attenuate the neurotoxic effects of Aβ in the ageing brain. These findings encourage fu-
ture studies to confirm the neuroprotective role of plaque-associated astrocytes and elucidate
the precise mechanism(s) which may aid in the development of novel therapeutic strategies.
Conclusions
Reactive astrocytes in close proximity to either diffuse or compact plaques may have a neuro-
protective role in the ageing brain, and possession of at least one copy of the ApoEε4 allele im-
pacts the astroglial response to Aβ plaques.
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